Paradoxically, dysregulated HDAC activity drives pathological stemness in cancer stem cells (CSCs), where aberrant deacetylation stabilizes oncogenic transcription programs (e.g., Wnt/β-catenin, Notch) and confers therapy resistance (143). Here, HDAC9 is linked to cancer.